Evaluation of imlifidase to reduce donated blood antibody titers

Ended Cooperative Agreement Awarded

Award ID
FA86502426K14
Recipient
Awarding agency
Obligated
$349,944

Award facts

Assistance listing
12.800 Air Force Defense Research Sciences Program
Completion date
Funding agency
Air Force Department of Defense
Place of performance
United States

Award details come from USAspending.gov.

About this award

Written by GovTribe AI ·

This federal Cooperative Agreement award, with a total funding amount of $349,944.00, was granted by the U.S. Air Force under the Defense Research Sciences Program (CFDA 12.800) to the University of Cincinnati's Sponsored Research Services Division. The purpose of this award is to conduct an EVALUATION OF IMLIFIDASE TO REDUCE DONATED BLOOD ANTIBODY TITERS. The award period runs from April 16, 2024 to July 16, 2025. The University of Cincinnati is a leading research institution that frequently partners with federal agencies to perform scientific research, educational initiatives, and community outreach programs. Through this Cooperative Agreement, the university will utilize its expertise in biomedical research to evaluate the effectiveness of the drug imlifidase in reducing antibody titers in donated blood.

Quick answers

Who received award FA86502426K14?

FA86502426K14 was awarded to Cincinnati Univ Of by Air Force Research Laboratory (Air Force Materiel Command) on April 16, 2024.

How much is award FA86502426K14 worth?

$349,944 has been obligated on FA86502426K14.

Which agency awarded FA86502426K14?

Air Force Research Laboratory (Air Force Materiel Command) awarded FA86502426K14, with funding from Air Force (Department of Defense).

On GovTribe

See this award's full record

  • Every transaction and subaward
  • The recipient's other awards and teaming partners
  • Similar grant awards
  • Ask GovTribe AI about this award
Try for free Login